Cystic Fibrosis Community Celebrates New Treatment Option
![](https://allianceforpatientaccess.org/wp-content/uploads/2023/11/AdobeStock_82741087-1024x683.jpeg)
The Food and Drug Administration approved a new drug that helps address the underlying cause of cystic fibrosis, not simply its symptoms. The drug, a combination of tezacaftor/ivacaftor, is for patients aged 12 and older with certain cystic fibrosis mutations.